| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
PI3K/Akt and NF-κB signaling pathways. Ganoderic acid I inhibits tumor cell proliferation, induces apoptosis, and suppresses metastasis by modulating PI3K/Akt and NF-κB signaling pathways. The compound also protects liver function by reducing oxidative stress and inflammatory cytokine production. As a lanostane-type triterpenoid, it may interact with multiple cellular targets involved in cell survival, proliferation, inflammation, and oxidative stress responses. The compound's hepatoprotective effects are mediated through its antioxidant and anti-inflammatory activities.
|
|---|---|
| ln Vitro |
Ganoderic acid I inhibits tumor cell proliferation, induces apoptosis, and suppresses metastasis in various cancer cell lines. It modulates PI3K/Akt and NF-κB signaling pathways, leading to reduced cell survival and proliferation. The compound also exhibits hepatoprotective effects by reducing oxidative stress and inflammatory cytokine production. Its anti-inflammatory activity is mediated through inhibition of inflammatory mediators. The compound's specific in vitro activities depend on the concentrations tested and the assay systems used. Further studies are needed to fully characterize its activity profile.
|
| ln Vivo |
Ganoderic acid I has been shown to protect liver function in vivo by reducing oxidative stress and inflammatory cytokine production. As a triterpenoid from Ganoderma lucidum, it may contribute to the pharmacological effects of Reishi mushroom, which has been used in traditional medicine for its health-promoting properties. The compound's anticancer, hepatoprotective, and anti-inflammatory activities suggest potential benefits in various disease models. Further in vivo studies are needed to characterize its specific pharmacokinetic and pharmacodynamic properties, as well as its efficacy and safety profile.
|
| Enzyme Assay |
Non-cell-based assays for ganoderic acid I include enzyme inhibition studies to assess its effects on PI3K/Akt and NF-κB signaling components. Kinase activity assays using purified enzymes or cell lysates can measure the compound's inhibitory effects. Antioxidant activity is assessed using DPPH radical scavenging, ABTS, and FRAP assays. Anti-inflammatory activity is measured by inhibition of COX-2, LOX, or cytokine production in enzyme assays. Standard analytical methods including HPLC, NMR, and mass spectrometry are used for compound characterization and purity assessment.
|
| Cell Assay |
Cell-based assays for ganoderic acid I use various cancer cell lines to assess its antiproliferative and pro-apoptotic activities. Cells are cultured in appropriate medium and treated with the compound at various concentrations. Cell viability is measured using MTT, CCK-8, or SRB assays. Apoptosis is evaluated by flow cytometry using Annexin V/PI staining, caspase activity assays, and detection of apoptotic markers by Western blot. PI3K/Akt and NF-κB pathway activation are assessed by Western blot. For hepatoprotective studies, hepatocyte cell lines are treated with hepatotoxic agents with or without the compound.
|
| Animal Protocol |
In vivo studies of ganoderic acid I are limited. Based on its biological activities, potential animal models include: tumor xenograft models for anticancer evaluation; CCl₄- or APAP-induced liver injury models for hepatoprotective evaluation; and carrageenan-induced paw edema models for anti-inflammatory evaluation. Standard protocols for these models involve administration of the compound followed by measurement of relevant endpoints including tumor volume, liver enzymes, inflammatory markers, and histopathological analysis.
|
| ADME/Pharmacokinetics |
Ganoderic acid I has a molecular formula of C₃₀H₄₄O₈ and a molecular weight of 532.67 g/mol. The CAS number is 98665-20-4. The IUPAC name is (3β,7β,20ξ)-3,7,20-trihydroxy-11,15,23-trioxo-Lanost-8-en-26-oic acid. The compound is a natural product from Ganoderma lucidum. It is a triterpenoid with a lanostane-type structure. Purity is ≥95%. The compound is almost insoluble in water (0.032 g/L at 25°C) and should be stored under recommended conditions.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for ganoderic acid I are limited. As a natural triterpenoid from Ganoderma lucidum, it is generally considered to have low toxicity. The compound exhibits anticancer, hepatoprotective, and anti-inflammatory activities, suggesting potential therapeutic benefits rather than toxicity. However, comprehensive toxicological studies have not been reported. Standard laboratory safety practices should be followed when handling this compound, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
Ganoderic acid I is a lanostane-type triterpenoid compound isolated from the medicinal mushroom Ganoderma lucidum (Reishi). Ganoderma lucidum has been used in traditional medicine for its health-promoting properties. Ganoderic acid I exhibits potent anticancer, hepatoprotective, and anti-inflammatory activities. It inhibits tumor cell proliferation, induces apoptosis, and suppresses metastasis by modulating PI3K/Akt and NF-κB signaling pathways. It also protects liver function by reducing oxidative stress and inflammatory cytokine production. The compound is considered a valuable natural product for developing treatments targeting cancer, liver diseases, and chronic inflammation. It is for research use only.
|
| Molecular Formula |
C30H44O8
|
|---|---|
| Molecular Weight |
532.67
|
| Exact Mass |
532.303
|
| CAS # |
98665-20-4
|
| PubChem CID |
73657195
|
| Appearance |
White to light yellow solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
725.8±60.0 °C at 760 mmHg
|
| Flash Point |
406.7±29.4 °C
|
| Vapour Pressure |
0.0±5.3 mmHg at 25°C
|
| Index of Refraction |
1.577
|
| LogP |
1.45
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
38
|
| Complexity |
1120
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O[C@H]1C[C@H]2C(C)(C)[C@H](CC[C@]2(C)C2C(C[C@]3(C)[C@@H](C(C)(CC(CC(C(=O)O)C)=O)O)CC([C@@]3(C)C=21)=O)=O)O
|
| InChi Key |
ZWMMEKXOLCCKLA-OCYWOBKISA-N
|
| InChi Code |
InChI=1S/C30H44O8/c1-15(25(36)37)10-16(31)13-29(6,38)20-12-22(35)30(7)24-17(32)11-19-26(2,3)21(34)8-9-27(19,4)23(24)18(33)14-28(20,30)5/h15,17,19-21,32,34,38H,8-14H2,1-7H3,(H,36,37)/t15-,17+,19+,20-,21+,27+,28-,29+,30+/m1/s1
|
| Chemical Name |
(2R,6S)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-4-oxoheptanoic acid
|
| Synonyms |
Ganoderic acid I
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (187.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8773 mL | 9.3867 mL | 18.7733 mL | |
| 5 mM | 0.3755 mL | 1.8773 mL | 3.7547 mL | |
| 10 mM | 0.1877 mL | 0.9387 mL | 1.8773 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
